CryoPort Inc (CYRX)

Cryoport Reports First Quarter 2026 Financial ResultsMay 4, 2026 4:05 PM
PR Newswire (US) First quarter revenue grew 16% year-over-year to $47.8 millionCommercial cell and gene therapy (CGT) revenue grew 26% year-over-year to $9.1 million, reflecting continued expansion in approved CGT programsLife Sciences Services revenue increased 18% year-over-year, led by 21% growth in BioStorage/BioServices Life Sciences Products revenue increased 15% year-over-year, driven by strong demand for cryogenic systems Supporting a record 766 global clinical trials and 21 commercially approved CGTs as of March 31, 2026Company raises full-year revenue guidance to $192 million - $196 millionNASHVILLE, Tenn., May 4, 2026 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or the "Company"), a leading global provider of integrated temperature-controlled supply chain solutions for the life sciences, today announced financial results for its first quarter (Q1) of 2026. Jerrell Shelton, CEO of Cryoport, commented, "Cryoport delivered a strong start to 2026 with first-quarter revenue of $47.8 million, up 16% year-over-year, reflecting a continuation of our momentum over the past several quarters across our integrated services and products platform. Revenue in support of commercial Cell and Gene Therapies (CGT) grew 26% to $9.1 million, while clinical trial support revenue grew 18% to $12.9 million. We continue to support one of the industry's broadest CGT pipelines, and our leadership across both clinical and commercial programs positions us well for sustainable growth."Our Life Sciences Services segment delivered another strong quarter, with revenue increasing 18% year-over-year, including 21% growth in BioStorage/BioServices. This performance reflects the increasing scope and complexity of the Cell & Gene Therapy programs we support and underscores the critical role we play in supporting our clients with our integrated, temperature-controlled supply chain services."Our Life Sciences Products segment also performed very well, generating 15% revenue growth, driven by global demand for MVE Biological Solutions' cryogenic systems. MVE continues to innovate and further solidify its position as the global leader in high-quality cryogenic systems."This growth across both our reporting segments, combined with solid gross margins and continued operational discipline, drove a $2.2 million year-over-year improvement in adjusted EBITDA from continuing operations, advancing us meaningfully along our "pathway to profitability.""Looking ahead, we see multiple growth catalysts extending beyond 2026, including the planned launch of BioServices operations at our Global Supply Chain Center in Paris, France in the third quarter, and the planned opening of our new Global Supply Chain Center in Santa Ana, California in the fourth quarter. These strategic investments expand our global footprint in key geographies and further strengthen our ability to support the advancement and commercialization of life-saving therapies globally. Reflecting on our strong performance in the first quarter and increased visibility into the remainder of the year, we are raising our full-year revenue guidance to $192 million to $196 million," concluded Mr. Shelton.The following table presents Q1 2026 revenue compared with Q1 2025:Cryoport, Inc. and Subsidiaries


Revenue 



Three Months Ended
March 31,
(unaudited)(in thousands)20262025% ChangeLife Sciences Services$              26,898$              22,86518 %BioLogistics Solutions21,66818,53117 %BioStorage/BioServices 5,2304,33421 %Life Sciences Products$              20,900$              18,17515 %Total Revenue$              47,798$              41,04016 %BioLogistics Solutions revenue increased 17% year-over-year in Q1 2026, driven by increasing customer activity, continued commercial product maturation, and clinical advancement within the CGT market. BioStorage/BioServices revenue grew 21% year-over-year, reflecting strong demand for our expanded, integrated services offering, which provides seamless, secure handling of temperature-sensitive materials across our global network.Revenue from the support of commercial CGTs increased 26% year-over-year to $9.1 million and as of March 31, 2026, the number of commercial therapies we support increased to 21.As of March 31, 2026, Cryoport supported a total of 766 global clinical trials, a net increase of 55 clinical trials over March 31, 2025, with 91 of these clinical trials in Phase 3. The number of trials by phase and region are as follows: Cryoport Supported Clinical Trials by PhaseClinical TrialsMarch 31,202420252026Phase 1286304318Phase 2312328357Phase 3777991Total675711766



Cryoport Supported Clinical Trials by RegionClinical TrialsMarch 31,202420252026Americas518544569EMEA112118143APAC454954Total675711766In Q1 2026, four Biologics License Applications (BLA) / Marketing Authorization Applications (MAA) filings occurred. During the first quarter, Cryoport's customer, Rocket Pharmaceuticals, received U.S. Food and Drug Administration (FDA) accelerated approval for their gene therapy KRESLADI™ for the treatment of pediatric patients with severe leukocyte adhesion deficiency-I (LAD-I). Severe LAD-I is an ultra-rare, life-threatening pediatric genetic immunodeficiency characterized by recurrent infections and high early-childhood mortality without treatment. For the balance of 2026, we anticipate another 10 possible BLA/MAA application filings and 8 additional new therapy approvals.Operational milestonesLife Sciences ServicesBioServices launch at our Global Supply Chain Center in Paris, France, expected in Q3, 2026.Continued progress toward the launch of our state-of-the-art Global Supply Chain Center in Santa Ana, California, expected in Q4, 2026.First cryopreserved clinical trial patient materials shipped in Q1 for two of our clients at our IntegriCell® facilities in Belgium and the U.S.Cryoport Systems named Best Logistics & Supply Chain Management Supplier - Digital Technology & Software at the 2026 Asia Pacific Biopharma Excellence Awards in Singapore.Life Sciences ProductsMVE Biological Solutions (MVE) introduced its new Fusion® 800 Series, the next evolution of MVE's patented, award-winning Fusion technology, a self-sustaining cryogenic freezer that eliminates the need for a continuous liquid nitrogen (LN2) supply feed, delivering exceptional reliability, safety, and sustainability in a compact footprint designed for space-constrained environments.Release of MVE HE (High Efficiency) cryogenic storage systems series integrated with the new MVE CryoVerse™ Connect Controller platform.Financial HighlightsOn June 11, 2025, the Company completed the divestiture of its CRYOPDP specialty courier business to DHL Group as part of a strategic partnership. The results of CRYOPDP, a former business within Cryoport's Life Sciences Services segment, are presented as discontinued operations for all periods and are excluded from the non-GAAP financial measures in this release.RevenueTotal revenue for Q1 2026 was $47.8 million, compared to $41.0 million for Q1 2025, a year-over-year increase of 16%, or $6.8 million. Life Sciences Services revenue for Q1 2026 (representing 56% of our total revenue) was $26.9 million, compared to $22.9 million for Q1 2025, up 18% year-over-year, including BioStorage/BioServices revenue of $5.2 million, up 21% year-over-year. Life Sciences Products revenue for Q1 2026 (representing 44% of our total revenue) was $20.9 million, compared to $18.2 million for Q1 2025, up 15% year-over-year.Gross MarginTotal gross margin was 45.8% for Q1 2026, compared to 45.4% for Q1 2025. Gross margin for Life Sciences Services was 48.9% for Q1 2026, compared to 47.9% for Q1 2025. Gross margin for Life Sciences Products was 41.9% for Q1 2026, compared to 42.3% for Q1 2025.Operating Costs and ExpensesOperating costs and expenses were $31.5 million for Q1 2026, compared to $25.8 million for Q1 2025.Loss from Continuing OperationsLoss from continuing operations was $9.4 million for Q1 2026, compared to a loss of $6.7 million for Q1 2025. Net Loss – including Discontinued OperationsNet loss was $10.5 million for Q1 2026, compared to net loss of $12.0 million for Q1 2025.Net loss attributable to common stockholders for Q1 2026 was $12.5 million, or $0.25 per share, compared to net loss attributable to common stockholders of $14.0 million, or $0.28 per share for Q1 2025.Adjusted EBITDA from Continuing OperationsAdjusted EBITDA from continuing operations was a negative $0.6 million for Q1 2026, compared to a negative $2.8 million for Q1 2025.Cash, Cash equivalents, and Short-Term InvestmentsCryoport held $403.6 million in cash, cash equivalents, and short-term investments as of March 31, 2026.Note: All reconciliations of GAAP to adjusted (non-GAAP) figures above are detailed in the reconciliation tables included later in the press release.Additional InformationFurther information on Cryoport's financial results is included in the attached condensed consolidated balance sheets and statements of operations, and additional explanations of Cryoport's financial performance are provided in the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2026, which is expected to be filed with the SEC on May 4, 2026. Additionally, the full report will be available in the SEC Filings section of the Investor Relations section of Cryoport's website at www.cryoportinc.com.Earnings Conference Call InformationIMPORTANT INFORMATION: In addition to the earnings release, a document titled "Cryoport First Quarter 2026 in Review", providing a review of Cryoport's business update, will be issued at 4:05 p.m. ET on Monday, May 4, 2026. The document is designed to be read in advance of the questions and answers conference call and will be accessible at https://ir.cryoportinc.com/news-events/ir-calendar.Cryoport management will host a conference call at 5:00 p.m. ET on May 4, 2026. The conference call will be in the format of a questions and answers session and will address any queries investors have regarding the Company's reported results. A slide deck will accompany the call.Conference Call InformationDate:Monday, May 4, 2026Time:5:00 p.m. ETDial-in numbers:1-800-717-1738 (U.S.), 1-646-307-1865 (International)Confirmation code:Request the "Cryoport Call" or Conference ID: 1191652Live webcast:'Investor Relations' section at www.cryoportinc.com or click here.
Please allow 10 minutes prior to the call to visit this site to download and install any necessary audio software.The questions and answers call will be recorded and available approximately three hours after completion of the live event in the Investor Relations section of the Company's website at www.cryoportinc.com for a limited time. To access the replay of the questions and answers click here. A dial-in replay of the call will also be available to those interested, until May 11, 2026. To access the replay, dial 1-844-512-2921 (United States) or 1-412-317-6671 (International) and enter replay entry code: 1191652#.About Cryoport, Inc.Cryoport, Inc. (Nasdaq: CYRX) is a leading global provider of integrated temperature-controlled supply chain solutions for the life sciences, with an emphasis on regenerative medicine. We support biopharmaceutical companies, contract manufacturers (CDMOs), contract research organizations (CROs), developers, and researchers with a comprehensive suite of services and products designed to minimize risk and maximize reliability across the temperature-controlled supply chain for the life sciences. Our integrated supply chain platform includes the Cryoportal® Logistics Management Platform, advanced temperature-controlled packaging, informatics, specialized biologistics, biostorage, bioservices, cryopreservation services, and cryogenic systems, which in varying combinations deliver end-to-end solutions that meet the rigorous demands of the life sciences. With innovation, regulatory compliance, and agility at our core, we are "Enabling the Future of Medicine™." Headquartered in Nashville, Tennessee, our company maintains a strong global presence with operations across the Americas, EMEA, and APAC.For more information, visit www.cryoportinc.com or follow via LinkedIn at https://www.linkedin.com/company/cryoportinc or @cryoport on X, formerly known as Twitter at https://x.com/cryoport for live updates.Forward-Looking StatementsStatements in this press release which are not purely historical, including statements regarding the Company's intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, those related to the Company's industry, business, long-term growth prospects, plans, strategies, acquisitions, future financial results and financial condition, such as the Company's outlook and guidance for full-year 2026 revenue and the related assumptions and factors expected to drive revenue, projected growth trends in the markets in which the Company operates, the Company's plans and expectations regarding the launch of new products and services, such as the expected timing and benefits of such products and services launches, the Company's expectations about future benefits of its acquisitions, and anticipated regulatory filings, approvals, label/geographic expansions or moves to earlier lines of treatment approved with respect to the products of the Company's clients. Forward-looking statements also include those related to the Company's expectations about future benefits relating to the CRYOPDP divestiture and strategic partnership with DHL (collectively, the "DHL Transaction"), the Company's plans regarding its Global Supply Chain Centers, including expected timing of future openings, the Company's plans and expectations relating to its strategic pivot to expand its global partnerships, and the Company's expectation of revenue contribution from IntegriCell's cryopreservation service centers throughout 2026. It is important to note that the Company's actual results could differ materially from those in any such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, risks and uncertainties associated with the effects of changing economic and geopolitical conditions, supply chain constraints, inflationary pressures, tariffs and other trade restrictions, foreign currency fluctuations, trends in the products markets, any U.S federal government shutdown, variations in the Company's cash flow, market acceptance risks, and technical development risks. Additional risks and uncertainties relating to the DHL Transaction include, but are not limited to, the risk that any disruption resulting from the DHL Transaction may adversely affect our businesses and business relationships, including with employees and suppliers. The Company's business could be affected by other factors discussed in the Company's SEC reports, including in the "Risk Factors" section of its most recently filed periodic reports on Form 10-K and Form 10-Q, as well as in its subsequent filings with the SEC. The forward-looking statements contained in this press release speak only as of the date hereof and the Company cautions investors not to place undue reliance on these forward-looking statements. Except as required by law, the Company disclaims any obligation and does not undertake to update or revise any forward-looking statements in this press release.Cryoport, Inc. and Subsidiaries

Condensed Consolidated Statements of Operations


Three Months Ended
March 31,
(unaudited)(in thousands, except share and per share data)20262025Revenue

Life Sciences Services revenue$                   26,898$                   22,865Life Sciences Products revenue20,90018,175Total revenue47,79841,040Cost of revenue:

Cost of services revenue13,74711,920Cost of products revenue12,13810,479Total cost of revenue25,88522,399Gross margin21,91318,641Operating costs and expenses:

Selling, general and administrative27,62021,901Engineering and development3,9073,934Total operating costs and expenses:31,52725,835Loss from operations(9,614)(7,194)Other income (expense):

Investment income3,0901,573Interest expense(432)(583)Other expense, net(2,368)(300)Loss before provision for income taxes(9,324)(6,504)Provision for income taxes(108)(234)Loss from continuing operations$                   (9,432)$                   (6,738)Loss from discontinued operations, net(1,112)(5,243)Net loss$                 (10,544)$                 (11,981)Paid-in-kind dividend on Series C convertible preferred stock(2,000)(2,000)Net loss attributable to common stockholders$                 (12,544)$                 (13,981)Net loss per share attributable to common stockholders - basic and diluted$                     (0.25)$                     (0.28)Weighted average common shares issued and outstanding - basic and diluted49,897,81749,947,012 Cryoport, Inc. and Subsidiaries

Condensed Consolidated Balance Sheets


March 31,December 31,
20262025(in thousands)(unaudited)
Current assets

Cash and cash equivalents$                     272,912$                     250,494Short-term investments130,722160,714Accounts receivable, net39,00433,359Inventories21,75023,188Prepaid expenses and other current assets6,1478,419Total current assets470,535476,174Property and equipment, net89,80585,448Operating lease right-of-use assets39,29939,720Intangible assets, net138,721138,082Goodwill22,13722,400Deposits2,0462,092Deferred tax assets1,0661,073 Total assets $                     763,609$                     764,989


Current liabilities

Accounts payable and other accrued expenses                                         $                       15,937$                       15,283Accrued compensation and related expenses17,00712,980Deferred revenue2,314943Current portion of operating lease liabilities3,6414,133Current portion of finance lease liabilities419422Current portion of convertible senior notes, net185,390185,094Current portion of notes payable159163Total current liabilities224,867219,018Notes payable, net1,0271,087Operating lease liabilities, net39,17339,078Finance lease liabilities, net680741Deferred tax liabilities1,5801,354Other long-term liabilities663444Contingent consideration630629Total liabilities268,620262,351Total stockholders' equity494,989502,638Total liabilities and stockholders' equity$                     763,609$                     764,989Note Regarding Use of Non-GAAP Financial MeasuresTo supplement our financial statements, which are presented on the basis of U.S. generally accepted accounting principles (GAAP), the following non-GAAP measure of financial performance as defined in Regulation G of the Securities Exchange Act of 1934 is included in this release: adjusted EBITDA from continuing operations. Non-GAAP financial measures are not calculated in accordance with GAAP, are not based on any comprehensive set of accounting rules or principles and may be different from non-GAAP financial measures presented by other companies. Non-GAAP financial measures, including adjusted EBITDA from continuing operations, should not be considered as a substitute for, or superior to, measures of financial performance prepared in accordance with GAAP.Adjusted EBITDA from continuing operations is defined as loss from continuing operations adjusted for net interest expense, income taxes, depreciation and amortization expense, stock-based compensation expense, acquisition and integration costs, cost reduction initiatives, investment income, unrealized loss on investments, foreign currency loss, changes in fair value of contingent consideration and charges or gains resulting from non-recurring events, as applicable.Management believes that adjusted EBITDA from continuing operations provides a useful measure of Cryoport's operating results, a meaningful comparison with historical results and with the results of other companies, and insight into Cryoport's ongoing operating performance. Further, management and the Company's board of directors utilize adjusted EBITDA from continuing operations to gain a better understanding of Cryoport's comparative operating performance from period to period and as a basis for planning and forecasting future periods. Adjusted EBITDA from continuing operations is also a significant performance measure used by Cryoport in connection with its incentive compensation programs. Management believes adjusted EBITDA from continuing operations, when read in conjunction with Cryoport's GAAP financials, is useful to investors because it provides a basis for meaningful period-to-period comparisons of Cryoport's ongoing operating results, including results of operations, against investor and analyst financial models, helps identify trends in Cryoport's underlying business and in performing related trend analyses, and it provides a better understanding of how management plans and measures Cryoport's underlying business.Cryoport, Inc. and Subsidiaries

Reconciliation of GAAP loss from continuing operations to adjusted EBITDA(unaudited)


Three Months Ended
March 31,
20262025(in thousands)

GAAP loss from continuing operations$          (9,432)$            (6,738)Non-GAAP adjustments to loss:

Depreciation and amortization expense6,4026,134Acquisition and integration costs—1Cost reduction initiatives—216Investment income(3,090)(1,573)Unrealized loss on investments2,105193Foreign currency loss454245Interest expense, net432583Stock-based compensation expense2,3953,064Change in fair value of contingent consideration15(5,178)Income taxes108234Adjusted EBITDA from continuing operations$             (611)$            (2,819)  View original content to download multimedia:https://www.prnewswire.com/news-releases/cryoport-reports-first-quarter-2026-financial-results-302761639.htmlSOURCE Cryoport, Inc. Original: Cryoport Reports First Quarter 2026 Financial Results

Cryoport to Report First Quarter 2026 Financial Results on May 4, 2026April 20, 2026 4:05 PM
PR Newswire (US)

NASHVILLE, Tenn., April 20, 2026 /PRNewswire/ -- Cryoport, Inc. (Nasdaq: CYRX) ("Cryoport" or the "Company"), a leading global provider of integrated temperature-controlled supply chain solutions for the life sciences, today announced that the Company will report financial results for the first quarter ended March 31, 2026 on Monday, May 4, 2026 after U.S. markets close.







In addition to the earnings release, a document titled "Cryoport First Quarter 2026 in Review", providing a review of Cryoport's financial and operational performance and a general business update, will be issued at 4:05 p.m. ET on Monday, May 4, 2026. The document is designed to be read in advance of the questions and answers conference call and will be accessible at https://ir.cryoportinc.com/news-events/ir-calendar.Cryoport management will host a conference call the same day at 5:00 p.m. ET. The conference call will be in the format of a questions and answers session and will address questions members of the investment community have regarding the Company's reported results. A slide deck will accompany the call.Conference Call InformationDate:Time:Monday, May 4, 20265:00 p.m. ETDial-in numbers:1-800-717-1738 (U.S.), 1-646-307-1865 (International)Confirmation code:Request the "Cryoport Call" or Conference ID: 1191652Live webcast:'Investor Relations' section at www.cryoportinc.com or click here.Please allow 10 minutes prior to the call to visit this site to download and install any necessary audio software.The questions and answers call will be recorded and available approximately three hours after completion of the live event in the Investor Relations section of the Company's website at www.cryoportinc.com for a limited time. To access the replay of the questions and answers click here. A dial-in replay of the call will also be available to those interested, until May 11, 2026. To access the replay, dial 1-844-512-2921 (United States) or 1-412-317-6671 (International) and enter replay entry code: 1191652#.About Cryoport, Inc
Cryoport, Inc. (Nasdaq: CYRX), is a leading global provider of integrated, temperature-controlled supply chain solutions for the life sciences, with an emphasis on regenerative medicine. We support biopharmaceutical companies, contract manufacturers (CDMOs), contract research organizations (CROs), developers, and researchers with a comprehensive suite of services and products designed to minimize risk and maximize reliability across the temperature-controlled supply chain for the life sciences. Our integrated supply chain platform includes the Cryoportal® Logistics Management Platform, advanced temperature-controlled packaging, informatics, specialized biologistics, biostorage, bioservices, cryopreservation services, and cryogenic systems, which in varying combinations deliver end-to-end solutions that meet the rigorous demands of the life sciences. With innovation, regulatory compliance, and agility at our core, we are "Enabling the Future of Medicine™."Headquartered in Nashville, Tennessee, our company maintains a strong global presence with operations across the Americas, EMEA, and APAC.For more information, visit www.cryoportinc.com or follow via LinkedIn at https://www.linkedin.com/company/cryoportinc or @cryoport on X at www.x.com/cryoport for live updates.Forward-Looking Statements
Statements in this press release which are not purely historical, including statements regarding Cryoport's intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. It is important to note that Cryoport's actual results could differ materially from those in any such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, risks and uncertainties associated with the effect of changing economic and geopolitical conditions, supply chain constraints, inflationary pressures, the effects of foreign currency fluctuations, trends in the products markets, variations in Cryoport's cash flow, market acceptance risks, and technical development risks. Cryoport's business could be affected by other factors discussed in Cryoport's SEC reports, including in the "Risk Factors" section of its most recently filed periodic reports on Form 10-K and Form 10-Q, as well as in its subsequent filings with the SEC. The forward-looking statements contained in this press release speak only as of the date hereof and Cryoport cautions investors not to place undue reliance on these forward-looking statements. Except as required by law, Cryoport disclaims any obligation, and does not undertake to update or revise any forward-looking statements in this press release.



View original content to download multimedia:https://www.prnewswire.com/news-releases/cryoport-to-report-first-quarter-2026-financial-results-on-may-4-2026-302747651.htmlSOURCE Cryoport, Inc.

Original: Cryoport to Report First Quarter 2026 Financial Results on May 4, 2026

At the Leerink Partners Global Healthcare Conference in Florida this past week Leerink put out a flash note on Cryoport and one of the many positive comments were"Importantly, the FY26 revenue guide
does not assume contributions from new approvals, which require
time for reimbursement, treatment center setup, and patient ramp."

Cryoport Reports Fourth Quarter and Full-Year 2025 Financial ResultsMarch 3, 2026 4:05 PM
PR Newswire (US)

FY 2025 revenue increased to $176.2 million, exceeding the high end of previous guidanceLife Sciences Services revenue grew 18% year-over-year in FY 2025, including a 22% rise in BioStorage/BioServices revenue Commercial cell and gene therapy revenue increased 29% year-over-year to $33.4 million in FY 2025Supported a record 760 global clinical trials and 20 commercially approved therapies as of December 31, 2025Full-year 2026 revenue guidance of $190 million to $194 million (8%-10% growth y-o-y)NASHVILLE, Tenn., March 3, 2026 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or the "Company"), a leading global provider of integrated temperature-controlled supply chain solutions for the life sciences, today announced financial results for its fourth quarter (Q4) and year ended (FY) December 31, 2025.







Jerrell Shelton, CEO of Cryoport, commented, "2025 was a year of strong progress for Cryoport. We delivered full-year revenue of $176.2 million, exceeding the high end of our previous guidance and reflecting continued momentum across our core markets. We achieved double-digit revenue growth driven by expanding cell and gene therapy ("CGT") activity, with revenue from the support of commercial CGTs increasing 29% year-over-year to a record $33.4 million for FY 2025. Revenue from the support of clinical trials also remained solid, growing 14% to $47.1 million for FY 2025. At year-end, we supported a record 760 global clinical trials, representing approximately 70% of CGT trials. We believe our leadership position across both clinical and commercial programs, and the breadth of the development pipeline we support, provide a substantial foundation for sustained long-term growth."We continued to execute on our strategy of expanding our revenue streams and capturing more revenue per client as our Life Sciences Services revenue increased 18% year-over-year for FY 2025, including 22% growth in BioStorage/BioServices revenue. This performance reflects the expanding scale of the clinical and commercial programs we support and the increasing value customers place on our differentiated high-end supply chain solutions. While our primary focus remains on accelerating revenue growth and strengthening our market position, we continue to enhance operational discipline across the organization as we advance on our pathway to profitability. In 2025, our cost reduction initiatives contributed to our consolidated gross margin of 47% and a $12 million year-over-year improvement in adjusted EBITDA from continuing operations."Despite macro challenges, our Life Sciences Products segment grew 7% year-over-year and continues to support our Services businesses. MVE Biological Solutions' (MVE) focus on innovation and execution continues to further enhance its position as the global leader in the production of high- quality cryogenic systems. Recently MVE introduced integrated Condition Monitoring Solutions for its dry vapor shippers and also launched the Fusion® 800 Series, a revolutionary self-sustaining cryogenic freezer that can fit through a single door, which opens up substantial market opportunities."We also increased our investments into Cryoport Systems to support the traction that we are seeing across our broad portfolio of CGT clients. These targeted investments include the launch of our Global Supply Chain Center in Paris, France, the expansion of our Belgian operations to accommodate a key commercial client, and the facility buildout to consolidate three existing facilities in Irvine, California into one expansive Global Supply Chain Center in Santa Ana, California."Importantly, in 2025 we formed a strategic partnership with DHL Group, which included DHL's acquisition of CRYOPDP, providing a substantial capital infusion. Over time, we believe this relationship will enhance our positioning in the EMEA and APAC regions and strengthen our competitive industry profile. As part of our continuing strategic initiative to embed our market-leading solutions into the CGT ecosystem and improve our growth trajectory, we expanded our global partnerships by entering into strategic collaborations with Cardinal Health and Parexel."As we enter 2026 and balance the global macro puts and takes, we believe that our full-year revenue guidance of $190 million to $194 million is an appropriate starting point for the year," concluded Mr. Shelton.In tabular form, Q4 2025 and FY 2025 revenue compared to Q4 2024 and FY 2024, respectively, were as follows:Cryoport, Inc. and Subsidiaries





Revenue 






Three Months Ended
December 31,
(unaudited)Years Ended
December 31,(in thousands)20252024% Change20252024% ChangeLife Sciences Services$           25,005$           21,47616 %$           96,497$           82,04418 %BioLogistics Solutions20,30517,47916 %78,13767,01917 %BioStorage/BioServices 4,7003,99718 %18,36015,02522 %Life Sciences Products$           20,445$           19,9762 %$           79,680$           74,7257 %Total Revenue$           45,450$           41,45210 %$         176,177$         156,76912 %BioLogistics Solutions revenue increased 17% year-over-year for FY 2025, supported by increasing customer activity and program advancement within the CGT market. BioStorage/BioServices revenue continued to experience strong year-over-year growth, increasing 22% for FY 2025, reflecting our clients' interest in our expanded and integrated services offering that provides a seamless and secure handling of temperature-sensitive materials through our global network.Revenue from the support of commercial CGTs increased 29% year-over-year to $33.4 million and we supported twenty (20) commercial therapies as of December 31, 2025.As of year-end, Cryoport supported a total of 760 global clinical trials, a net increase of 59 clinical trials over FY 2024, with 86 of these clinical trials in Phase 3. The number of trials by phase and region are as follows: Cryoport Supported Clinical Trials by PhaseClinical TrialsDecember 31,202320242025Phase 1282299313Phase 2311321361Phase 3828186Total675701760



Cryoport Supported Clinical Trials by RegionClinical TrialsDecember 31,202320242025Americas519537571EMEA112116138APAC444851Total675701760



In Q4 2025, five Biologics License Applications (BLA) / Marketing Authorization Applications (MAA) filings occurred. Post quarter-end, two additional BLA filings have occurred. During the fourth quarter, Cryoport's customer, Fondazione Telethon received FDA approval for their gene therapy Waskyra for the treatment of Wiskott-Aldrich Syndrome (WAS). During the fourth quarter, Bristol Myers Squibb received supplemental approval from the European Commission (EC) to expand the label of Breyanzi® as a third line treatment for relapsed or refractory follicular lymphoma. Lastly, in late December, Cryoport's customer Inovio Pharmaceuticals' BLA filing for INO-3107 was accepted by the FDA as a potential treatment for adults with Recurrent Respiratory Papillomatosis (RRP). For 2026, we anticipate 13 BLA/MAA application filings (including the two already filed), nine new therapy approvals and an additional two approvals for label/geographic expansions. In the near term, Cryoport has three clients that are anticipating new therapy approval decisions in March and April 2026.Operational milestonesLife Sciences ServicesLaunched state-of-the-art Global Supply Chain Center at the Charles de Gaulle airport in Paris, France, with our fourth Global Supply Chain Center in Santa Ana, California targeted for opening in late 2026. IntegriCell®, with cryopreservation service centers located near Liège, Belgium and in Houston, Texas, onboarded its first clients from whom we will have revenues throughout 2026.Launched cGMP sterile fulfillment/kitting services out of our Liège, Belgium facility supporting manufacturing needs for a key commercial client and the broader market. Cryoport Systems successfully achieved certification under ISO 21973:2020, the international standard for transportation of cells for therapeutic use published by the International Organization for Standardization (ISO), underscoring its commitment to safety and traceability within supply chain management of the rapidly expanding CGT industry.Life Sciences ProductsMVE Biological Solutions (MVE) introduced its integrated Condition Monitoring Solutions for its SC 4/2V and 4/3V dry vapor shippers, combining MVE's trusted cryogenic systems with advanced, real-time condition monitoring technology supplied by Tec4med, a Cryoport company. MVE launched its new Fusion® 800 Series, the next evolution of MVE's patented, award-winning Fusion technology, a self-sustaining cryogenic freezer that eliminates the need for a continuous liquid nitrogen (LN2) supply, delivering exceptional reliability, safety, and sustainability in a compact footprint designed for space-constrained environments.Financial HighlightsOn June 11, 2025, the Company completed its previously announced divestiture of its specialty courier CRYOPDP business to DHL Supply Chain International Holding B.V. ("DHL") as a part of a strategic partnership with DHL. The divestiture and strategic partnership are expected to enhance the Company's ability to develop its business, particularly in the EMEA and APAC regions, and to provide differentiated and high-value services aligned with Cryoport's long-term growth strategy. The results of CRYOPDP, a former business within Cryoport's Life Sciences Services segment, are presented as discontinued operations for all periods presented within the Condensed Consolidated Statements of Operations and Condensed Consolidated Balance Sheets included in this press release and are also not included in the non-GAAP financial measures presented herein.RevenueTotal revenue for Q4 2025 was $45.5 million, compared to $41.5 million for Q4 2024, a year-over-year increase of 10%, or $4.0 million. Life Sciences Services revenue for Q4 2025 (representing 55% of our total revenue) was $25.0 million, compared to $21.5 million for Q4 2024, up 16% year-over-year, including BioStorage/BioServices revenue of $4.7 million, up 18% year-over-year. Life Sciences Products revenue for Q4 2025 (representing 45% of our total revenue) was $20.4 million, compared to $20.0 million for Q4 2024, up 2% year-over-year.Total revenue for FY 2025 was $176.2 million, compared to $156.8 million for FY 2024, a year-over-year increase of 12%, or $19.4 million. Life Sciences Services revenue for FY 2025 was $96.5 million, compared to $82.0 million for FY 2024, up 18% year-over-year, including BioStorage/BioServices revenue of $18.4 million for FY 2025, compared to $15.0 million for FY 2024, up 22% year-over-year.Life Sciences Products revenue for FY 2025 was $79.7 million, compared to $74.7 million for FY 2024, up 7% year-over-year.Gross MarginTotal gross margin was 47.8% for Q4 2025, compared to 47.0% for Q4 2024. Gross margin for Life Sciences Services was 48.6% for Q4 2025, compared to 48.8% for Q4 2024. Gross margin for Life Sciences Products was 46.8% for Q4 2025, compared to 45.1% for Q4 2024.Total gross margin was 47.1% for FY 2025 compared to 44.4% for FY 2024. Gross margin for Life Sciences Services was 48.8% for FY 2025, compared to 46.9% for FY 2024. Gross margin for Life Sciences Products was 45.2% for FY 2025, compared to 41.7% for FY 2024.Operating Costs and ExpensesOperating costs and expenses were $31.7 million for Q4 2025, compared to $32.2 million for Q4 2024. Operating costs and expenses for FY 2025 decreased to $119.9 million, compared to $191.3 million for FY 2024. The decrease for FY 2025 reflects an impairment charge of $63.8 million in Q2 2024, which was primarily related to the write off of remaining goodwill for MVE. Excluding the impairment charge, non-GAAP adjusted operating costs and expenses for FY 2025 were $119.9 million, compared to $127.5 million for FY 2024.Loss from Continuing OperationsLoss from continuing operations was $8.5 million for Q4 2025, compared to a loss of $17.2 million for Q4 2024. Loss from continuing operations for FY 2025 was $34.0 million compared to a loss of $104.7 million for FY 2024.Net Income (Loss) – including Discontinued OperationsNet loss for Q4 2025 was $11.6 million and net income for FY 2025 was $78.3 million, compared to net losses of $18.7 million and $114.8 million for the same periods in 2024, respectively. Net income for FY 2025 was primarily driven by the divestiture of our CRYOPDP specialty courier business during Q2 2025, which contributed $112.3 million, net of taxes, to income from discontinued operations.Net loss attributable to common stockholders for Q4 2025 was $13.6 million, or $0.27 per share. Net income attributable to common stockholders for FY 2025 was $70.3 million, or $1.40 per share. This compares to net losses attributable to common stockholders of $20.7 million, or $0.42 per share, and $122.8 million, or $2.49 per share, for Q4 2024 and FY 2024, respectively.Non-GAAP adjusted net loss was $34.0 million for FY 2025, compared to $69.5 million for FY 2024.Adjusted EBITDA from Continuing OperationsAdjusted EBITDA from continuing operations was a negative $1.4 million for Q4 2025, compared to a negative $2.9 million for Q4 2024. Adjusted EBITDA from continuing operations for FY 2025 was a negative $5.8 million, compared to a negative $17.8 million for FY 2024.Cash, Cash equivalents, and Short-Term InvestmentsCryoport held $411.2 million in cash, cash equivalents, and short-term investments as of December 31, 2025.Share Repurchase ProgramsDuring 2025, the Company purchased 1,340,608 shares of its common stock under its repurchase programs, at an average price of $7.45 per share, for an aggregate amount of $10.0 million. These shares were returned to the status of authorized but unissued shares of common stock. Following these repurchases, the Company had approximately $63.9 million in total repurchase authorization available under its remaining repurchase program.Guidance for Full-Year Fiscal 2026The Company provides full-year 2026 revenue guidance in the range of $190.0 million to $194.0 million. The Company's 2026 guidance is dependent on its current business and expectations, which may be impacted by, among other things, factors that are outside of our control, such as national economic factors, the global macroeconomic and geopolitical environment, supply chain constraints, inflationary pressures, any U.S. federal government shutdown, tariffs and other trade restrictions and/or the effects of foreign currency fluctuations, as well as the other factors described in the Company's filings with the Securities and Exchange Commission ("SEC"), including in the "Risk Factors" section of its most recently filed periodic reports on Form 10-K and Form 10-Q, as well as in its subsequent filings with the SEC. Note: All reconciliations of GAAP to adjusted (non-GAAP) figures above are detailed in the reconciliation tables included later in the press release.Additional InformationFurther information on Cryoport's financial results is included in the attached condensed consolidated balance sheets and statements of operations, and additional explanations of Cryoport's financial performance are provided in the Company's Annual Report on Form 10-K for the year ended December 31, 2025, which is expected to be filed with the SEC on March 6, 2026. Additionally, the full report will be available in the SEC Filings section of the Investor Relations section of Cryoport's website at www.cryoportinc.com.Earnings Conference Call InformationIMPORTANT INFORMATION: In addition to the earnings release, a document titled "Cryoport Fourth Quarter and Full Year 2025 in Review", providing a review of Cryoport's business update, will be issued at 4:05 p.m. ET on Tuesday, March 3, 2026. The document is designed to be read in advance of the questions and answers conference call and will be accessible at https://ir.cryoportinc.com/news-events/ir-calendar.Cryoport management will host a conference call at 5:00 p.m. ET on March 3, 2026. The conference call will be in the format of a questions and answers session and will address any queries investors have regarding the Company's reported results. A slide deck will accompany the call.Conference Call InformationDate:Tuesday, March 3, 2026Time:5:00 p.m. ETDial-in numbers:1-800-717-1738 (U.S.), 1-646-307-1865 (International)Confirmation code:Request the "Cryoport Call" or Conference ID: 1189463Live webcast:'Investor Relations' section at www.cryoportinc.com or click here. Please allow 10 minutes prior to the call to visit this site to download and install any necessary audio software.The questions and answers call will be recorded and available approximately three hours after completion of the live event in the Investor Relations section of the Company's website at www.cryoportinc.com for a limited time. To access the replay of the questions and answers click here. A dial-in replay of the call will also be available to those interested, until March 10, 2026. To access the replay, dial 1-844-512-2921 (United States) or 1-412-317-6671 (International) and enter replay entry code: 1189463#.About Cryoport, Inc.Cryoport, Inc. (Nasdaq: CYRX is a leading global provider of integrated, temperature-controlled supply chain solutions for the life sciences, with an emphasis on regenerative medicine. We support biopharmaceutical companies, contract manufacturers (CDMOs), contract research organizations (CROs), developers, and researchers with a comprehensive suite of services and products designed to minimize risk and maximize reliability across the temperature-controlled supply chain for the life sciences. Our integrated supply chain platform includes the Cryoportal® Logistics Management Platform, advanced temperature-controlled packaging, informatics, specialized biologistics, biostorage, bioservices, cryopreservation services, and cryogenic systems, which in varying combinations deliver end-to-end solutions that meet the rigorous demands of the life sciences. With innovation, regulatory compliance, and agility at our core, we are "Enabling the Future of Medicine™." Headquartered in Nashville, Tennessee, our company maintains a strong global presence with operations across the Americas, EMEA, and APAC.For more information, visit www.cryoportinc.com or follow via LinkedIn at https://www.linkedin.com/company/cryoportinc or @cryoport on X, formerly known as Twitter at https://x.com/cryoport for live updates.Forward-Looking Statements
Statements in this press release which are not purely historical, including statements regarding the Company's intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, those related to the Company's industry, business, long-term growth prospects, plans, strategies, acquisitions, future financial results and financial condition, such as the Company's outlook and guidance for full-year 2026 revenue and the related assumptions and factors expected to drive revenue, projected growth trends in the markets in which the Company operates, the Company's plans and expectations regarding the launch of new products and services, such as the expected timing and benefits of such products and services launches, the Company's expectations about future benefits of its acquisitions, and anticipated regulatory filings, approvals, label/geographic expansions or moves to earlier lines of treatment approved with respect to the products of the Company's clients. Forward-looking statements also include those related to the Company's expectations about future benefits relating to the CRYOPDP divestiture and strategic partnership with DHL (collectively, the "DHL Transaction"), the Company's plans regarding its Global Supply Chain Centers, including expected timing of future openings, the Company's plans and expectations relating to its strategic pivot to expand its global partnerships, and the Company's expectation of revenue contribution from IntegriCell's cryopreservation service centers throughout 2026. It is important to note that the Company's actual results could differ materially from those in any such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, risks and uncertainties associated with the effects of changing economic and geopolitical conditions, supply chain constraints, inflationary pressures, tariffs and other trade restrictions, foreign currency fluctuations, trends in the products markets, any U.S federal government shutdown, variations in the Company's cash flow, market acceptance risks, and technical development risks. Additional risks and uncertainties relating to the DHL Transaction include, but are not limited to, the risk that any disruption resulting from the DHL Transaction may adversely affect our businesses and business relationships, including with employees and suppliers. The Company's business could be affected by other factors discussed in the Company's SEC reports, including in the "Risk Factors" section of its most recently filed periodic reports on Form 10-K and Form 10-Q, as well as in its subsequent filings with the SEC. The forward-looking statements contained in this press release speak only as of the date hereof and the Company cautions investors not to place undue reliance on these forward-looking statements. Except as required by law, the Company disclaims any obligation and does not undertake to update or revise any forward-looking statements in this press release.Cryoport, Inc. and Subsidiaries



Condensed Consolidated Statements of Operations




Three Months Ended
December 31,
(unaudited)Years Ended
December 31,(in thousands, except share and per share data)2025202420252024Revenue



Life Sciences Services revenue$                  25,005$                  21,476$                  96,497$                  82,044Life Sciences Products revenue20,44519,97679,68074,725Total revenue45,45041,452176,177156,769Cost of revenue:



Cost of services revenue12,85910,98749,42943,564Cost of products revenue10,88010,97243,69443,548Total cost of revenue23,73921,95993,12387,112Gross margin21,71119,49383,05469,657Operating costs and expenses:



Selling, general and administrative27,27628,091102,819109,809Engineering and development4,4664,15517,04117,710Impairment loss---63,809Total operating costs and expenses:31,74232,246119,860191,328Loss from operations(10,031)(12,753)(36,806)(121,671)Other income (expense):



Investment income3,3571,4279,7989,895Interest expense(634)(578)(2,361)(3,977)Gain on extinguishment of debt, net---18,505Other income (expense), net(87)(5,402)(2,801)(7,101)Income (loss) before provision for income taxes(7,395)(17,306)(32,170)(104,349)Provision for income taxes(1,126)134(1,799)(359)Income (loss) from continuing operations$                  (8,521)$                (17,172)$                (33,969)$              (104,708)Income (loss) from discontinued operations, net(3,123)(1,497)112,270(10,048)Net income (loss)$                (11,644)$                (18,669)$                  78,301$              (114,756)Paid-in-kind dividend on Series C convertible preferred stock(2,000)(2,000)(8,000)(8,000)Net income (loss) attributable to common stockholders$                (13,644)$                (20,669)$                  70,301$              (122,756)Net income (loss) per share attributable to common stockholders:



Basic$                    (0.27)$                    (0.42)$                      1.40$                    (2.49)Weighted average common shares issued and outstanding:



Basic49,759,26449,616,80650,071,66549,349,624 Cryoport, Inc. and Subsidiaries

Condensed Consolidated Balance Sheets


December 31,
20252024(in thousands)

Current assets

Cash and cash equivalents$                    250,494$                      34,137Short-term investments160,714216,460Accounts receivable, net33,35925,304Inventories23,18821,476Prepaid expenses and other current assets8,4197,943Current assets held for sale-36,251Total current assets476,174341,571Property and equipment, net85,44880,013Operating lease right-of-use assets39,72039,920Intangible assets, net138,082147,927Goodwill22,40020,569Deposits2,0921,951Deferred tax assets1,073842Long-term assets held for sale-70,699 Total assets $                    764,989$                    703,492


Current liabilities

Accounts payable and other accrued expenses$                      15,283$                      15,895Accrued compensation and related expenses12,98011,209Deferred revenue9431,061Current portion of operating lease liabilities4,1333,399Current portion of finance lease liabilities422315Current portion of convertible senior notes, net185,09414,298Current portion of notes payable163143Current portion of contingent consideration-2,808Current liabilities held for sale-15,435Total current liabilities219,01864,563Convertible senior notes, net-183,919Notes payable, net1,0871,114Operating lease liabilities, net39,07838,551Finance lease liabilities, net741800Deferred tax liabilities1,354804Other long-term liabilities444295Contingent consideration, net6293,751Long-term liabilities held for sale-7,797    Total liabilities262,351301,594    Total stockholders' equity502,638401,898    Total liabilities and stockholders' equity$                    764,989$                    703,492Note Regarding Use of Non-GAAP Financial MeasuresTo supplement our financial statements, which are presented on the basis of U.S. generally accepted accounting principles (GAAP), the following non-GAAP measures of financial performance as defined in Regulation G of the Securities Exchange Act of 1934 are included in this release: adjusted operating costs and expenses, adjusted net loss, and adjusted EBITDA from continuing operations. Non-GAAP financial measures are not calculated in accordance with GAAP, are not based on any comprehensive set of accounting rules or principles and may be different from non-GAAP financial measures presented by other companies. Non-GAAP financial measures, including adjusted operating costs and expenses, adjusted net loss, and adjusted EBITDA from continuing operations, should not be considered as a substitute for, or superior to, measures of financial performance prepared in accordance with GAAP.Adjusted operating costs and expenses is defined as operating costs and expenses, excluding impairment losses, if any. Adjusted net loss is defined as net income (loss), excluding impairment losses, net gain on extinguishment of debt, and income (loss) from discontinued operations, including gain on sale, if any. Management believes these measures, when read in conjunction with, and as supplemental to, the corresponding GAAP financial measures, provide useful measures to investors of Cryoport's expenses and operating results, meaningful comparisons with historical results, and insight into Cryoport's operating performance.Adjusted EBITDA from continuing operations is defined as loss from continuing operations adjusted for net interest expense, income taxes, depreciation and amortization expense, stock-based compensation expense, acquisition and integration costs, cost reduction initiatives, investment income, unrealized loss on investments, foreign currency loss, net gain on extinguishment of debt, impairment loss, changes in fair value of contingent consideration and charges or gains resulting from non-recurring events, as applicable.Management believes that adjusted EBITDA from continuing operations provides a useful measure of Cryoport's operating results, a meaningful comparison with historical results and with the results of other companies, and insight into Cryoport's ongoing operating performance. Further, management and the Company's board of directors utilize adjusted EBITDA from continuing operations to gain a better understanding of Cryoport's comparative operating performance from period to period and as a basis for planning and forecasting future periods. Adjusted EBITDA from continuing operations is also a significant performance measure used by Cryoport in connection with its incentive compensation programs. Management believes adjusted EBITDA from continuing operations, when read in conjunction with Cryoport's GAAP financials, is useful to investors because it provides a basis for meaningful period-to-period comparisons of Cryoport's ongoing operating results, including results of operations, against investor and analyst financial models, helps identify trends in Cryoport's underlying business and in performing related trend analyses, and it provides a better understanding of how management plans and measures Cryoport's underlying business.Cryoport, Inc. and Subsidiaries



Reconciliation of GAAP operating cost and expenses to Non-GAAP adjusted operating cost and expenses





Three Months Ended
December 31,
(unaudited)Years Ended
December 31,
2025202420252024(in thousands)



GAAP operating costs and expenses$        31,742$             32,246$      119,860$      191,328Non-GAAP adjustments to operating costs and expenses



Impairment loss———(63,809)Non-GAAP adjusted operating costs and expenses$        31,742$             32,246$      119,860$      127,519




Cryoport, Inc. and Subsidiaries



Reconciliation of GAAP net income (loss) to Non-GAAP adjusted net income (loss)







Three Months Ended
December 31,
(unaudited)Years Ended
December 31,
2025202420252024(in thousands)



GAAP net income (loss)$      (11,644)$           (18,670)$        78,301$    (114,756)Non-GAAP adjustments to net income (loss)



Income (loss) from discontinued operations, including gain on sale(3,123)—112,270—Gain on extinguishment of debt, net———18,505Impairment loss———(63,809)Non-GAAP adjusted net loss$        (8,521)$           (18,670)$      (33,969)$      (69,452) Cryoport, Inc. and Subsidiaries



Reconciliation of GAAP loss from continuing operations to adjusted EBITDA

(unaudited)




Three Months Ended
December 31,Years Ended
December 31,
2025202420252024(in thousands)



GAAP loss from continuing operations$          (8,521)$          (17,172)$         (33,969)$      (104,708)Non-GAAP adjustments to loss:



Depreciation and amortization expense6,3555,99225,15323,565Acquisition and integration costs6375655Cost reduction initiatives—310642842Investment income(3,357)(1,427)(9,798)(9,895)Unrealized loss on investments822,4457025,038Foreign currency loss2483,1302,7692,352Interest expense, net6345792,3613,977Stock-based compensation expense2,4313,64410,06616,567Gain on extinguishment of debt, net———(18,505)Impairment loss———63,809Change in fair value of contingent consideration—(225)(5,178)(1,827)Income taxes1,126(134)1,799359Other adjustments(401)—(401)—Adjusted EBITDA from continuing operations$          (1,397)$            (2,855)$           (5,779)$         (17,771) 



View original content to download multimedia:https://www.prnewswire.com/news-releases/cryoport-reports-fourth-quarter-and-full-year-2025-financial-results-302703027.htmlSOURCE Cryoport, Inc.

Original: Cryoport Reports Fourth Quarter and Full-Year 2025 Financial Results

Cryoport's MVE Biological Solutions Introduces New Fusion® 800 SeriesFebruary 11, 2026 8:30 AM
PR Newswire (US)

Self-Sustaining Fusion® 800 Series Cryogenic Freezer Delivers High-Capacity Storage, Flexibility,
and Cost Benefits in Limited Space EnvironmentsNASHVILLE, Tenn., Feb. 11, 2026 /PRNewswire/ -- Cryoport, Inc. (Nasdaq: CYRX) ("Cryoport" or the "Company"), a leading global provider of temperature-controlled supply chain solutions for the life sciences, today announced the launch of the MVE Fusion® 800 Series, the next evolution of MVE Biological Solutions' patented, award-winning Fusion technology. This self-sustaining cryogenic freezer eliminates the need for a continuous liquid nitrogen (LN2) supply, delivering exceptional reliability, safety, and sustainability in a compact footprint designed for space-constrained environments.







Recognized with the ISBER Outstanding New Product Award, MVE's Fusion technology transforms cryogenic storage. The new Fusion 800 builds on this innovative platform, offering the same trusted performance and energy efficiency in a lab-sized design. At just 32 inches wide, it fits through standard doorways for easy installation without costly facility modifications."The Fusion 800 is a major evolution and a step forward into the future," said Mike Duich, President and CEO of MVE Biological Solutions. "Fusion 800 delivers the storage density, flexibility, and operational freedom our customers demand without the infrastructure burden of traditional cryogenic systems. This product opens the door for more facilities to safely adopt true cryogenic storage.""Truly transformative products are rare in this industry, but the MVE Fusion 800 is one of them," said Jerrell Shelton, CEO of Cryoport. "It solves a longstanding challenge in cryogenic storage by protecting critical biological materials and life-saving therapies without the space and infrastructure requirements of legacy cryogenic storage systems. We believe the Fusion 800 is on a path to becoming the new standard in research facilities and hospital pharmacies worldwide."Ideal for medical research facilities, clinical development operations, hospital pharmacies and clinics, biorepositories, and blood and tissue banks, etc., the Fusion 800 offers versatile storage options for vials, blood bags, cassettes, etc., maintaining steady state temperatures at or below -150°C.For more information on the MVE Fusion® 800 Series, visit: https://mvebio.com/ or consult with an MVE distributor.About Cryoport, Inc
Cryoport, Inc. (Nasdaq: CYRX), is a leading global provider of temperature-controlled supply chain solutions for the life sciences, with an emphasis on regenerative medicine. We support biopharmaceutical companies, contract manufacturers (CDMOs), contract research organizations (CROs), developers, and researchers with a comprehensive suite of services and products designed to minimize risk and maximize reliability across the temperature-controlled supply chain for the life sciences. Our integrated supply chain platform includes the Cryoportal® Logistics Management Platform, advanced temperature-controlled packaging, informatics, specialized biologistics, biostorage, bioservices, cryopreservation services, and cryogenic systems, which in varying combinations deliver end-to-end solutions that meet the rigorous demands of the life sciences. With innovation, regulatory compliance, and agility at our core, we are "Enabling the Future of Medicine™."Headquartered in Nashville, Tennessee, our company maintains a strong global presence with operations across the Americas, EMEA, and APAC.For more information, visit www.cryoportinc.com or follow via LinkedIn at https://www.linkedin.com/company/cryoportinc or @cryoport on X, formerly known as Twitter at www.x.com/cryoport for live updates.Forward-Looking Statements
Statements in this press release which are not purely historical, including statements regarding Cryoport's intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. It is important to note that Cryoport's actual results could differ materially from those in any such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, risks and uncertainties associated with the effect of changing economic and geopolitical conditions, supply chain constraints, inflationary pressures, the effects of foreign currency fluctuations, trends in the products markets, variations in Cryoport's cash flow, market acceptance risks, and technical development risks. Cryoport's business could be affected by other factors discussed in Cryoport's SEC reports, including in the "Risk Factors" section of its most recently filed periodic reports on Form 10-K and Form 10-Q, as well as in its subsequent filings with the SEC. The forward-looking statements contained in this press release speak only as of the date hereof and Cryoport cautions investors not to place undue reliance on these forward-looking statements. Except as required by law, Cryoport disclaims any obligation, and does not undertake to update or revise any forward-looking statements in this press release.



View original content to download multimedia:https://www.prnewswire.com/news-releases/cryoports-mve-biological-solutions-introduces-new-fusion-800-series-302684810.htmlSOURCE Cryoport, Inc.

Original: Cryoport's MVE Biological Solutions Introduces New Fusion® 800 Series

FYI.. Anktiva sales are up 700% yoy. CYRX ships this treatment for ImmunityBio. This is just one of the many companys that CYRX services that is accelerating at a rapid pace.

With the recent sale of Cryopdp to DHL and the acceleration of cell and gene therapy use, Cryoport is in the best position they have ever been to grow and execute their long term plans for profitability and share holder value.

Still losing faith here?

What do you make of the last month's awful returns? Does CYRX bounce back? Long term CYRX holder and I'm losing faith here....

Big run. The numbers are good. Look at the fine print.

CYRX 10Q due March 12

Cryoport Inc. is a global provider of temperature-controlled and cold chain logistics solutions for temperature-sensitive life sciences commodities1. The company serves the biopharmaceutical industry with logistics solutions for biologic materials and regenerative medicine, including immunotherapies, stem cells and CAR T-cells1. Cryoport’s mission is to support life and health by providing reliable and comprehensive temperature-controlled supply chain solutions for the life sciences through its advanced technologies and dedicated personnel2.

Some of the products and services that Cryoport offers are:

Cryoport Express® liquid nitrogen dry vapor shippers, which can maintain temperatures below -150°C for up to 10 days3.
C3™ 2-8°C solution, which is a reusable, validated, and environmentally friendly packaging system that can keep materials between 2°C and 8°C for up to 96 hours3.
Cryoportal® logistics management platform, which is a cloud-based software that enables end-to-end visibility, tracking, and monitoring of shipments across the globe3.
Smartpak II® condition monitoring system and geo-sensing technology, which provide real-time data on location, temperature, orientation, humidity, pressure, and shock3.
Chain of Compliance®, which ensures full compliance at every step in the transportation process, from packaging to delivery3.
Clinical & Commercial Support, which provides dedicated project management, logistics coordination, and customer service teams to assist clients with their supply chain needs3.
Veri-Clean®, which is a validated cleaning process that eliminates the risk of cross-contamination and ensures the integrity of the shippers3.
BioServices, which include cell processing, storage, distribution, kitting, and biobanking solutions for cell and gene therapies4.
Cryoport has its headquarters in Brentwood, Tennessee. Its Global Supply Chain Centers are located in Houston, Texas and Morris Plains, New Jersey. Its Global Logistics Centers are located in Irvine, California; Amsterdam, The Netherlands; Sydney, Australia and Singapore5.

Cryoport is the leader in temperature-controlled supply chain solutions for the life sciences industry. It has over 650 active clinical trials, 10 commercial products, 650,000+ shipments, and 150+ countries served3. It also has a strong financial performance, with a revenue growth of 23% year-over-year in 2022.

I am really surprised this stock got down to these levels?

Ouch! weaker than expected global demand for capital equipment; clinical trial start delays; and slower than expected ramps from certain clients
Second quarter revenue expected in the range of $56.5 - $57.5 million
Full year 2023 revenue now expected in the range of $233 - $243 million

https://otp.tools.investis.com/clients/us/cryoport/SEC/sec-show.aspx?Type=html&FilingId=16787658&CIK=0001124524&Index=10000

New Bullish SA Article

https://seekingalpha.com/article/4615166-cryoport-cyrx-strong-player-cold-chain-logistics-solid-growth-prospects

I remain bullish on CYRX due to its dominant position in cold-chain logistics, comprehensive range of services, significant growth potential, and capable management team. As the field of cell and gene therapy experiences more regulatory filings and approvals, CYRX is well-positioned to benefit from the overall industry growth. Additionally, CYRX can leverage its existing cryogenic offerings by pursuing strategic mergers and acquisitions in the cold-chain solutions space. I view the stock as a buy and have an end-of-year price target of $25 on the stock.

Best of luck with your investments!

10 Commercial Therapies at the end of Q1 2023

As of the end of the first quarter, Cryoport supported 10 commercial therapies and a total of 652 clinical trials globally, with 82 of these in Phase 3. We expect up to an additional 18 anticipated application filings, 10 new therapy approvals and an additional 11 label or geographic expansion approvals in 2023.

https://seekingalpha.com/article/4600358-cryoport-inc-cyrx-q1-2023-earnings-call-transcript

Q3 Growth Story Picture



Best of luck with your investments!

First Quarter 2023 Results

Record revenue of $63 million, representing 20% growth year-over-year

Growth across all lines of business: Biopharma/Pharma revenue up 19%; Animal Health revenue up 30%; Reproductive Medicine revenue up 13% year-over-year

Commercial Cell and Gene Therapy revenue up 28% year-over-year, now supporting 82 Phase 3 clinical trials

Strong balance sheet with $523 million in cash and short-term investments

NASHVILLE, Tenn., May 4, 2023 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or the "Company"), a leading global provider of innovative temperature-controlled supply chain solutions for the life sciences, today announced financial results for the three months ended March 31, 2023.


Jerrell Shelton, CEO of Cryoport, commented, "We are pleased to report that we delivered record revenue of $62.8 million for the first quarter, representing top-line growth of 20% or 23% in constant currency compared to the first quarter of last year. This quarterly performance was driven by solid demand for our comprehensive set of products and services as we achieved double digit growth in each of our markets, Biopharma/Pharma, Reproductive Medicine, and Animal Health.

"We saw solid growth in Biopharma/Pharma with revenue increasing 19% year-over year. The Regenerative Medicine industry was one of the fastest growing therapeutic segments in 2022, with new innovative cell and gene therapies entering the market. This trend has continued in 2023 driving year-over-year growth in revenue from commercial therapies by 28% for the first quarter. Patient demand continues to outpace commercial cell therapy supply; however, biopharma companies and contract development and manufacturing organizations (CDMOs) are continuing to build out manufacturing capacity to meet patient demand and the expected future demand for cell and gene therapies. This bodes well for Cryoport as we believe that we are well positioned to support this expected growth with our advanced temperature-controlled supply chain solutions.

"Growth in Animal Health revenue for the quarter increased over 30% year-over-year. This was due to increases in our growing global population and its demand for animal protein as well as the expanding ownership of companion animals in developing and emerging regions. Companion animals are fueling the need for therapeutic innovation in this area to improve animals' lives. We are seeing increasing activity from top global animal health pharmaceutical companies to meet this demand.

"Reproductive Medicine revenue was $2.8 million for the first quarter of 2023 with revenue increasing 13% year-over-year. Growth was primarily driven by our continued progress in contracting with key reproductive clinic networks, as evidenced by our recent announcements regarding our support of Boston IVF and Inception Fertility.

"Looking ahead, given the current geopolitical instability and imbalance in the world economy, we remain committed to continuing our momentum throughout the remainder of 2023. We expect to benefit from growth in all our markets and especially the dynamic cell and gene therapy industry where Cryoport supports a total of 652 clinical trials globally with 82 of these in phase 3.

"As a leader in the development of advanced temperature-controlled supply chain solutions for the life sciences industry, we have recently launched the Cryoportal® v2 Logistics Management System. The Cryoportal® v2 is the first and, to our knowledge, the only ISPE GAMP® 5.0 validated system of its type to serve the life sciences and provides many new features and enhancements.

"Of course, we have not stopped there. Other key product and services initiatives planned for launch this year include our next generation, advanced Cryoport Elite™ shipper line, which is now starting to roll out with our ELITE™ Ultra-cold -80°C line of shippers supporting gene therapies. Cryoport ELITE™ shippers will provide additional de-risking, longer temperature hold-times, more advanced communications features, and new security controls. Near the end of the year, our SkyTrax™ Condition Monitoring System, a generational leap to an advanced condition monitoring system that will support temperature ranges from controlled room temperatures to cryogenic temperatures, will also be released as well.

"As we move forward, we expect the robust cell and gene therapy industry to continue its march forward and we will continue to provide new, innovative services and products that will drive our organic growth. Good examples of this are the build-out of our Global Supply Chain Center Network, the introduction of our IntegriCell™ platform to supply autologous and allogeneic cell therapies a standardized apheresis collection and end-to-end cryopreservation service for leukapheresis derived therapies, as well as our Fusion® and Vario® Cryogenic Freezer Systems.

"Our strategy and our team are committed to ensuring Cryoport is always delivering the highest quality, most reliable solutions to support life-saving cell and gene therapies, and we are constantly evaluating opportunities to ensure this – because we know 'a patient is waiting.'

"In my opinion, Cryoport is in a great position in the industry today and has never been stronger than it is today. We are looking forward to fulfilling our vision of becoming the essential supply chain company serving the life sciences," concluded Mr. Shelton.

Total revenues by market for the three months ended March 31, 2023, as compared to the same period in 2022 was as follows:


Best of luck with your investments!

Boston IVF Agreement: Reproductive Material Shipments Across the U.S.

Apr. 25, 2023 8:30 AM ET
NASHVILLE, Tenn., April 25, 2023 /PRNewswire/ -- Cryoport, Inc. (CYRX) (NASDAQ: CYRX) ("Cryoport" or the "Company"), a leading global provider of innovative temperature-controlled supply chain solutions for the life sciences, reproductive medicine and animal health industries, today announced that it has signed a new three-year agreement with Boston IVF, a pioneer in reproductive healthcare and innovative research and one of the world's most experienced fertility treatment providers.


Utilizing Cryoport's end-to-end supply chain solutions, Boston IVF will now have the ability to integrate its regional and satellite labs across Massachusetts, New Hampshire, Maine, Rhode Island, New York and Indiana, along with its partner sites in Delaware, Ohio, Idaho, Utah and North Carolina. Cryoport's platform will improve the overall efficiency of Boston IVF's reproductive material shipments and ensure significant risk mitigation for patients and families entrusting Boston IVF with their care.

"Boston IVF is a widely recognized leader for reproductive medicine, having supported more than 150,000 babies born since 1986 while achieving some of the highest IVF success rates in the country," said Jerrell Shelton, CEO of Cryoport. "As we seek to provide more patients with peace of mind that their reproductive materials are being handled safely and securely, we're proud to partner with a team that is equally committed to delivering the best outcomes and experiences for their patients."

"Inside our clinics, our physicians are among the best in treating infertility and have affiliations with the Beth Israel Deaconess Medical Center and Harvard Medical School," said David Stern, CEO of Boston IVF. "We're always looking for ways to ensure exceptional patient care from start to finish in each fertility journey, and this includes the vital logistical component outside of the clinic. Cryoport's cutting-edge technology and nonstop monitoring simplify the entire supply chain process by ensuring that patients' reproductive materials are safe every step of the way."

Best of luck with your investments!

That's a big if however if that does happen it should give them some good credibility.
Go Cryoport!

Approval Pipeline, as of Feb. 2023



That is the main slide I'm interested in as an investor.

That's where income growth can be boosted. If CYRX signs on 11 new approved therapies in 2023, that can only validate the entire growth approach, moving therapies from Ph I to Ph II to Ph III to commercial. Trials are at 654 as of Dec. 2022. From on quarter to the next, that's my first focus.

Best of luck with your investments!

Expanding Capabilities across Regions, Growth Factor



CYRX global footprint has expanded again, with more offerings on the entire logistical chain.

They are making themselves more attractive to their target companies as a one stop shop and establishing the foundation for a world wide operation and across functions. They keep betting on growth. A medium/long term strategy. Now the revenue needs to keep in line with the strategy, and so far, the pipeline points that way.

Best of luck with your investments!

Commercial Growth Pipeline, Feb. 2023



CYRX keeps adding more potential to their pipelines (and actual commercial on the backend. )

At the end of the year, we supported a total of 654 clinical trials worldwide, a net gain of 52 clinical trials since year-end 2021 and with 79 of these trials in Phase 3. At the end of the year, we also supported 10 commercial therapies, an increase from eight since year-end 2021.

The company also said it sees FY 2023 revenue of $270M to $290M, above the consensus estimate of $269.32M.

Best of luck with your investments!

SA Article

A fairly balanced view on CYRX, with the basic company overview, the possible catalysts, etc.

Conclusion:

We are constructive on CYRX's position in the life sciences value chain and believe the company has scope to rate higher, seeking upside targets to $38.5. Net-net, we rate CYRX a buy.

https://seekingalpha.com/article/4576204-cryoport-differentiated-offering-in-the-life-sciences-value-chain

Best of luck with your investments!

Blackrock increases CYRX position

https://www.nasdaq.com/articles/blackrock-increases-position-in-cryoport-cyrx

Probably the reason for the 10%+ PPS increase toay.

Best of luck with your investments!

And another partnership. The growth strategy is clear.

https://www.prnewswire.com/news-releases/cryoport-announces-new-strategic-partnership-with-syneos-health-to-advance-cell--gene-therapies-301724255.html

NASHVILLE, Tenn., Jan. 18, 2023 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport"), a leading global provider of innovative temperature-controlled supply chain solutions to the life sciences industry focused on the pharmaceutical and cell and gene therapy markets, today announced a new strategic partnership with Syneos Health® (NASDAQ: SYNH), the only fully integrated biopharmaceutical solutions organization purpose-built to accelerate customer success. Both Cryoport and Syneos Health are world leading solutions companies with deep expertise and experience supporting clinical and commercial stage therapies. The partnership will support the global advancement of cell and gene therapies, providing the industry's first fully integrated biopharmaceutical and supply chain solution.

The new partnership couples the full suite of clinical development services offered by Syneos Health with IntegriCell™, Cryoport's platform providing standardized apheresis collection through BioLife Cellular Therapy Services, (part of Takeda), cryopreservation services, risk mitigation services, logistics support, and secondary packaging.

Jerrell Shelton, CEO of Cryoport, said, "We are excited to be partnering with Syneos Health as our two companies share a common vision for advancing standardized cell and gene therapies in the clinical trial arena. Syneos Health strategically integrates clinical development, medical affairs and commercial capabilities to address modern market realities. Syneos Health understands the value and opportunity to the industry of integrating the first fully standardized apheresis collection and cryoprocessing platform, IntegriCell™, into their solutions offering. The work we are doing with Syneos Health underscores the value Cryoport brings to its partners as well as its customers and further enhances our leadership position in the global cell and gene industry."

Michael Brooks, COO, Syneos Health, said, "Leveraging our relationship with Cryoport, Syneos Health will help deliver seamless integration and insights for key services for cell and gene trial operations to biopharmaceutical customers. This partnership will further help to accelerate treatment timelines and improve outcomes by expanding patient access to these life-changing therapies worldwide."

The market seem to respond positively, at least today. CYRX's relentless strategy will bear fruit in the mid-term. Can't wait for a positive EPS. That will turn the PPS around.

Best of luck with your investments!

Bought another $17.41 slice today.

Best of luck with your investments!

Bullish SA Article

https://seekingalpha.com/article/4558376-cryoport-the-golden-stock

Conclusion

In all, I maintain my buy recommendation on Cryoport with a 5/5 stars rating. Cryoport is a special company for various reasons. As a logistic service provider, the company leverages the strong industry tailwind of cell/gene therapy innovators. Second, Cryoport grows aggressively both organically and through mergers and acquisitions. Despite the recent macroeconomic issues, the long-term future of Cryoport is brighter than ever. The company continues to ramp ups its revenues, clinical trials being supported, the opening of new centers, and acquisitions. If you are patient and leverage volatility to your advantage, Cryoport is most likely to give you a 10-bagger return in the next few years.

Best of luck with your investments!

Commercial Growth Pipeline



Best of luck with your investments!

Q3 2022: Headwinds - Ukraine, China Covid Policies, Inflation

Third quarter revenue of $60.5 million; nine months 2022 revenue reaches $176.9 million; Cryoport Systems' revenue up 25% year-over-year

$530 million in cash and short-term investments

Supporting a record 643 global clinical trials; 61 net new trials added (year-over-year)

Entered strategic relationship with Takeda's BioLife Plasma Services for apheresis collection and leukopak production

Record number of new products and offerings slated to be released by Cryoport in 2023

The bad news:
Like many companies that operate globally, we were subject to macroeconomic headwinds during the third quarter and expect some of these pressures will extend into the fourth quarter. Specifically, during the third quarter, we experienced a convergence of macroeconomic pressures that impacted revenue including: a negative foreign exchange impact of $2.6 million due to the increased strength of the U.S. dollar against certain foreign currencies; recurring COVID lockdowns in China; supply chain related issues; the Russia/Ukraine war and its ripple effect throughout Europe; and industry capacity limitations, which interfered with cell and gene therapy commercial revenue acceleration.

The good news:


Not the best of quarters and the headwinds will still be there for a couple of quarters at least (Ukraine, China policy). Yet, a solid foundation and a growth funnel that's looking excellent.

I will add to my position slowly and check the next quarter for more visibility in the 2023 guidance and for the revised aspirational goals of the company.

Best of luck with your investments!

SA Reference Article

A good summary of the investment thesis around CYRX as a growth company. It's a clear article, well organized, simple to read.

It captures why I invested in CYRX and why this is a medium/long term opportunity.

https://seekingalpha.com/article/4542593-cryoport-a-rare-investing-opportunity

The article goes over:
* An overview of the Company
* The Investment Thesis
* The industry Tailwinds
* EMEA Expansion - Belgium With Cell Matters Acquisition
* EMEA Expansion - Spain With Polar Express
* EMEA Expansion - France With Cell & Co BioServices
* Strategic Partnership With Takeda
* Operational Performance - Robust Expansion In All Business Segments
* Operational Performance - Supporting More Clinical Trials
* Competitor Landscape
* Financial Assessment
* Valuation Analysis
* Shares Repurchase Program
* Potential Risks
* Conclusion


Conclusion
In all, I maintain my buy recommendation on Cryoport with a 5/5 stars rating. Cryoport is a rare investment opportunity because it is profiting from the strong industry tailwind favoring cellular therapy innovators. So long as the cellular therapy sector continues to grow, leading companies like Cryoport (and BioLife) will enjoy more business, thus continuing to ramp up their topline growth. Over the years, the company would then bank a profit due to the economy of scale.

As it leverages growth with the sophisticated M/A approach, Cryoport can grow much faster than other firms. Over the years, Cryoport has been quite busy with making additive acquisitions. 2022 alone witnessed three significant buyouts - Cell&Co, Polar Expres, and Cell Matters. Then, there's the Takeda partnership.

Despite such strong growth, Cryoport is still a young company with substantial upsides. By purchasing shares in such a firm and holding it for many years, you can earn multi-bagger profits.

Best of luck with your investments!

CYRX down in the last couple of weeks, without any substantive news.
Staying long.

Best of luck with your investments!

Houston again, partnering with Takeda's BioLife Plasma Services

The Houston location will help the partnership synergy.

Cryoport Enters into Strategic Relationship with Takeda's BioLife Plasma Services
Cryoport plans to establish an integrated supply chain platform with BioLife Plasma Services to offer standardized cell therapy collection, processing, and storage services in United States and Europe over time

NASHVILLE, Tenn., Sept. 8, 2022 /PRNewswire/ -- Cryoport, Inc. (Nasdaq: CYRX) ("Cryoport" or the "Company"), a global leader in temperature-controlled supply chain solutions for the life sciences industry, today announced it has entered into a strategic relationship with BioLife Plasma Services, part of the global biopharmaceutical company Takeda, intended to provide consistent, high-quality cellular starting material for use in the manufacture of life-saving cellular therapies.


By bringing together BioLife Plasma Services' proficiency in apheresis collection and their donation center infrastructure with Cryoport's life sciences' world-class capabilities and expertise in temperature-controlled supply chain solutions for the biopharmaceutical industry, the companies aim to establish a standardized, integrated apheresis collection, processing, and distribution solution for cellular therapies. Importantly, the new platform will leverage the cryo-processing expertise of Cell Matters, which Cryoport acquired in late July 2022.

http://ir.cryoport.com/news-releases/2022/09-08-2022-133118452

CYRX keeps executing on their plan for growth and expansion.


Best of luck with your investments!

Two US Based Global Supply Chain Centers, Houston and Morris Plains!


An important milestone for us was, after two years of development, the opening of our first two Global Supply Chain Centers in Houston, Texas and Morris Plains, New Jersey during the second quarter of this year. Grand Opening ceremonies were held in June, and these centers are now fully staffed with trained personnel and are beginning to support client activity.

These world-class facilities form the foundation of our Global Supply Chain Center Network and, importantly, include the addition of GMP (Good Manufacturing Practices) BioServices to our increasingly comprehensive supply chain solutions.

CYRX grows the funnel and the production/services capacity. It's a growth story. The future is bright.

Best of luck with your investments!

Belgium Cell Matters acquisition

After France Cell&Co earlier this year, CYRX acquired another EMEA company:

In April, we expanded our presence in the EMEA region with the acquisition of Cell&Co BioServices in France, and subsequent to quarter end, we acquired Cell Matters, a Belgium based company specializing in cryo-process optimization, cryo-processing, and cryopreservation; thereby expanding our supply chain platform upstream in support of standardized apheresis collection and processing.

Our increasing portfolio of new products and services, coupled with our expanding global footprint is enabling us to become “the partner of choice” across the cell and gene therapy (CGT) industry as we provide new solutions to derisk supply chain processes.

CYRX Funnel Estimates

Aug 4th, 2022 Earnings Call

CYRX Growth by Region
Aug. 4, 2022 Earnings Call

CYRX Clinical Trial Funnel

Aug 4, 2022 Earnings Call

CYRX: Earnings Call Aug 4th:

The effect of the fire earlier this year should start to dissipate and the backlog could even boost this quarter's earnings.

Also curious about the distribution and volume of PI, PII, PIII and Commercial products supported.

Best of luck with your investments!

Bought more shares today.

CYRX Growth in 2 images - May 2022





Best of luck with your investments!

Commercial Outlook - May 2022
We expect another year of continued commercial revenue ramp as our clients focus on expanding their commercial manufacturing capabilities, as currently approved products receive supplemental approvals for new or expanding indications, and as anticipated product launches come to fruition.

Two (2) Cryoport supported Biologic License Applications (BLAs) or Marketing
Authorization Applications (MAAs) were filed in first quarter 2022, based on internal information and data from the Alliance for Regenerative Medicine.

During the quarter, there were three (3) approvals consisting of
> one (1) new product,
> one (1) geographic expansion and
> one (1) move to earlier line treatment.

Currently, we anticipate up to an additional fifteen filings, three (3) new
therapy approvals, and an additional seven (7) label or geographic expansion approvals in 2022.

For 2023, another 20 BLA or MAA filings are anticipated, up from twelve previously.
https://ir.cryoport.com/~/media/Files/C/Cryoport-IR/documents/events/q1-2022/first-quarter-2022-in-review.pdf

Best of luck with your investments!

Q1 Earning on 05/05/2022 - Confirmed.

Best of luck with your investments!

Bought more in the $22, so not completely playing with house money, but pretty close :)

Upcoming CC this week. The current valuation is way too low.

Best of luck with your investments!

Cell&Co BioServices acquisition: growth strategy.

CYRX is not kidding around. They are building a juggernaut. The latest acquisition:



Acquisition of Cell&Co BioServices, Clermont-Ferrand, France, accelerates Company's EMEA expansion plans and development of its Global Supply Chain Network

NASHVILLE, Tenn., April 18, 2022 /PRNewswire/ -- Cryoport, Inc. (Nasdaq: CYRX) ("Cryoport" or the "Company"), a global leader in temperature-controlled supply chain solutions for the life sciences industry, today announced that it has acquired Cell&Co BioServices, headquartered in Clermont-Ferrand, France with additional operations in Pont-du-Château, France. Founded in 2012, Cell&Co is a bioservices business providing biorepository, kitting, and logistics services to the life sciences industry. Its accreditations include ISO 9001, ANSM (Investigational Medicinal Products), NFS 96 900, and soon, ISO 20387. Supporting its biostorage and services of clinical and commercial biopharma therapies, Cell&Co has in-house QP services.


In 2021, Cell&Co recorded revenue of approximately €2.6 million. Cryoport's purchase price for Cell&Co was €6.2 million, comprised of upfront consideration of €3.6 million in the form of cash and Cryoport common stock, plus a potential earn-out of €2.5M based on achieving certain financial targets.

Regarding the acquisition, Jerrell Shelton, Chief Executive Officer of Cryoport, stated, "We are indeed pleased to have the Cell&Co team as a part of Cryoport. Cell&Co will play a significant role in Cryoport Systems' development of its Global Supply Chain Network, designed to meet the needs of the growing Regenerative Medicine industry worldwide. In fact, on a global basis, industry experts expect that between now and 2027 approximately 30 to 50 new cell and gene therapies will be introduced into the market each year. Cell&Co's competencies combined with its location in the centre of France makes it an excellent strategic fit for Cryoport Systems and will accelerate the expansion of its new Global Supply Chain Network by approximately two years.

"Coupled with our new Global Supply Chain Centers in Houston, Texas and Morris Plains, New Jersey, Cell&Co will add significantly to the development of Cryoport Systems' global service offering. It will also provide Cryoport Systems with an EU site for importation services for non-EU clients, which will add significant value for our clients and create additional opportunities for U.S. based regenerative medicine developers looking to conduct clinical trials or commercially distribute cell and gene therapies in EMEA."

Sofien Dessolin and Florent Belon, founders of Cell&Co BioServices made a joint statement saying, "The cell and gene therapy market is expected to grow rapidly and is a significant focus for us. We are proud of the work we have accomplished and even more of joining the Cryoport group with its objective of making medical innovation achievable and more reliable for the benefit of patients around the world. It is a source of great pride and a huge motivating factor. The time was right for us to be part of an industry-leading organization such as Cryoport in order to support our business, expand our product solutions, and become a significantly larger player in the life sciences industry. We are excited to be part of Cryoport's strategic platform in the advanced therapies space in EMEA and look forward to continuing to lead Cell&Co as an integral part of Cryoport as it builds out its Global Supply Chain Network and other services."
http://ir.cryoport.com/news-releases/2022/04-18-2022-133044618

The Company is executing on the growth strategy!!!

Best of luck with your investments!

SA Article, another Bullish Analysis

https://seekingalpha.com/article/4501644-cryoport-industry-leader-basking-tailwinds

The conclusion:

In all, I maintain my buy recommendation on Cryoport with a five out of five stars rating. As you can appreciate, it's rare to find a growth company that leverages the M/A model, which is also an industry leader like Cryoport. Being the logistics provider for the growing cell/gene therapy innovators, Cryoport is basking in the industry tailwinds. Both organic and M/A revenues are growing and leaping aggressively. Concurrently, the company is building and expanding its infrastructures to support future growth. During this bear market, you have another chance to pick that same great company at a fraction of its intrinsic value. The management realized that their shares are trading at a bargain. As such, they are buying back shares.

The valuation analysis is worth reading. Lots of upside!

Best of luck with your investments!

CYRX at the Disruptive Biotech Enabling Technologies Mini Conference on April 7, 2022

SA Article

https://seekingalpha.com/article/4499176-cryoport-risky-investment-upside-potential

A few charts comparing PPS with net income, revenue, debt, total assets...

Best of luck with your investments!

New Prague facility returns to full production after fire

Q1 took a hit. CYRX says it's contained to Q1. Let's hope so.

Cryoport previously announced it would resume production at the New Prague facility during the week of February 14th and ramp up to full production during the first quarter of 2022.

The Company also guided to a revenue impact from the fire of $4 to $5 million limited to the first quarter of 2022. Production did resume as planned; however, a number of unexpected challenges resulting from the fire caused the recommissioning and validation of production to progress more slowly than had been previously anticipated.

As a result, Cryoport now expects a revenue impact from the fire of $9.0 to $9.5 million which will remain limited to the first quarter. As previously announced, the Company expects its insurance to cover the majority of the costs to restore and re-open the facility, as well as related business interruption losses. Management will concentrate on reducing shipment timelines to customers throughout the remainder of the year.

What insurance will cover is up for discussion. I think they are being optimistic.

Going to be a few Qs before the ship sails in smooth waters again and this fire is behind us.

Best of luck with your investments!

Gap up followed by a nice 9% move today (3/29/2022) thus far

I don't see news yet as to the reason behind it. The volume is below average (session is not closed yet), maybe just correcting after a very long down ramp (unjustified in my view, but that's the market).

I may be getting a bonus end of H1. If the PPS is still depressed, I might put back some money into CYRX. (I'm playing with house money for now after taking some nice benefit).

Best of luck with your investments!

Board's confidence in business model and outlook

At this stage in the company, I believe the board's confidence is warranted.

Jerrell Shelton, Cryoport CEO, said, "The authorization of the repurchase program reflects our constant focus on shareholder return and effective capital allocation. The authorization of this repurchase program demonstrates the Board's confidence in our business model and outlook, our financial performance, and our commitment to delivering value to our stakeholders. We plan to opportunistically repurchase shares of our common stock and convertible senior notes, while maintaining ample liquidity to support our growth organically and through potential acquisitions."

When the stock is undervalued, this capital allocation makes sense. (and not the only allocation necessarily). Quite opportunistic. I like the pragmatic approach.

Best of luck with your investments!